Health Canada has given Advanced Accelerator Applications approval to market its Lutathera, or lutetium-177 DOTATATE, as treatment for gastroenteropancreatic neuroendocrine tumors among adults with progressive disease.
Advanced Accelerator Applications' Lutathera approved in Canada
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.